Profound Medical to Unveil First CAPTAIN Trial Results on March 13

Event summary

  • Profound Medical will present first clinical outcomes from the CAPTAIN trial at EAU 2026 on March 13.
  • Investor call scheduled for March 13 at 11:30 a.m. EDT to discuss trial results and commercial implications.
  • Management to participate in one-on-one investor meetings at ROTH Conference March 22-24.
  • CAPTAIN trial compares TULSA Procedure with robotic radical prostatectomy in localized prostate cancer.

The big picture

Profound Medical's CAPTAIN trial results represent a pivotal moment in validating its TULSA Procedure as a non-invasive alternative to surgery for prostate cancer. The outcomes could influence treatment guidelines and expand the company's market reach in a competitive medical device landscape. With approvals across major global markets, Profound is positioning itself as a leader in incision-free, MRI-guided therapies.

What we're watching

Clinical Efficacy
How the CAPTAIN trial results will position the TULSA Procedure against robotic radical prostatectomy.
Regulatory Pathway
Whether positive data could accelerate inclusion in prostate cancer treatment guidelines.
Commercial Expansion
The pace at which Profound Medical can scale adoption of its MRI-guided therapies.